Mirum Pharmaceuticals Q3 net product sales surge, outlook raised
MIRM•Mirum Pharmaceuticals’ third-quarter net product sales rose to $185.72 million, while it posted a $40.77 million net loss. The company raised its 2026 net product sales guidance to $715 million-$720 million.
1. Sales and guidance
Mirum Pharmaceuticals reported third-quarter net product sales of $185.72 million, up year over year, and raised its 2026 net product sales guidance to $715 million-$720 million. Its third-quarter net loss was $40.77 million, with operating expenses of $245.47 million.
2. Product growth
LIVMARLI net product sales rose 45% year over year, which the company attributed to expansion into additional rare cholestatic liver diseases. Bile Acid Medicines sales grew 28%, reflecting increased demand for CHOLBAM and CTEXLI. Mirum received U.S. FDA approval and launched ATEBRIOZ for FOP.
